Lazard Asset Management
ZVRA icon

Lazard Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Lazard Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,959
Closed -$26K – 2390
2025
Q2 		$26K Buy
+2,959
New +$24K ﹤0.01% 2102

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Lazard Asset Management's ZVRA Position: Q3 2025 in Review

Lazard Asset Management sold out of Zevra Therapeutics (ZVRA) in Q3 2025, closing a stake of 2,959 shares — an estimated $26K sold.

Lazard Asset Management first reported a position in ZVRA in Q2 2025 and held it in 1 quarter. The position peaked at $26K in Q2 2025. 166 funds tracked by Wall St. Rank hold ZVRA as of Q3 2025.

  • Lazard Asset Management reported no remaining Zevra Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 2,959 Zevra Therapeutics shares in Q3 2025, an estimated $26K.
  • Lazard Asset Management first reported a position in Zevra Therapeutics in Q2 2025 and held it in 1 quarter.
  • Lazard Asset Management's Zevra Therapeutics position peaked at $26K in Q2 2025.
  • 166 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.